. 2024 Sep 27;5(5):929–939. doi: 10.1002/jha2.1013

TABLE 5.

Treatment‐emergent bleeding/bruising events by antithrombotic therapy class.

	Antithrombotic agents ^a
	Direct factor Xa inhibitors (n = 79)		Heparins (n = 40)		Platelet aggregation inhibitors (n = 112)		Salicylic acid and derivatives ^b (n = 12)		Thrombolytics ^c (n = 5)
Events	All grades n (%)	Grade ≥3 n (%)	All grades n (%)	Grade ≥3 n (%)	All grades n (%)	Grade ≥3 n (%)	All grades n (%)	Grade ≥3 n (%)	All grades n (%)	Grade ≥3 n (%)
Bleeding/bruising	37 (46.8)	2 (2.5)	22 (55.0)	1 (2.5)	49 (43.8)	4 (3.6)	4 (33.3)	1 (8.3)	3 (60)	0
Hematuria	4 (5.1)	0	2 (5)	0	7 (6.3)	0	0	0	0	0
Epistaxis	6 (7.6)	0	2 (5)	0	4 (3.6)	0	2 (16.7)	0	0	0
Gingival bleeding	3 (3.8)	0	1 (2.5)	0	2 (1.8)	0	0	0	0	0
Hemoptysis	1 (1.3)	0	2 (5)	0	2 (1.8)	0	0	0	1 (20)	0
Hemarthrosis	1 (1.3)	1 (1.3)	1 (2.5)	0	0	0	0	0	0	0
Hematochezia	2 (2.5)	1 (1.3)	0	0	0	0	0	0	0	0
Blood Loss anemia	0	0	0	0	1 (0.9)	0	0	0	0	0

Bleeding/bruising subcategories
Bruising ^d	22 (27.8)	12 (30)	0	32 (28.6)	0	3 (25.0)	0	2 (40)
Contusion	18 (22.8)	10 (25)	0	25 (22.3)	0	2 (16.7)	0	1 (20)
Petechiae	4 (5.1)	1 (2.5)	0	5 (4.5)	0	1 (8.3)	0	0
Ecchymosis	1 (1.3)	1 (2.5)	0	2 (1.8)	0	0	0	1 (20)
Increased tendency to bruise	1 (1.3)	0	0	2 (1.8)	0	0	0	0
Hemorrhage/hematoma ^d	13 (16.5)	10 (25)	1 (2.5)	18 (16.1)	4 (3.6)	2 (16.7)	1 (8.3)	1 (20)
Hematoma	2 (2.5)	5 (12.5)	0	3 (2.7)	0	1 (8.3)	0	0
Conjunctival hemorrhage	4 (5.1)	0	0	1 (0.9)	0	0	0	0
Upper gastrointestinal hemorrhage	0	0	0	3 (2.7)	2 (1.8)	0	0	0
Vitreous hemorrhage	1 (1.3)	1 (2.5)	0	1 (0.9)	0	0	0	0
Hemorrhage	1 (1.3)	0	0	0	0	0	0	0
Gastrointestinal hemorrhage	0	0	0	1 (0.9)	0	0	0	0
Postprocedural hemorrhage	0	1 (2.5)	1 (2.5)	1 (0.9)	1 (0.9)	1 (8.3)	1 (8.3)	0
Subdural hematoma	0	1 (2.5)	0	2 (1.8)	1 (0.9)	0	0	0
Pulmonary hemorrhage	0	0	0	0	0	0	0	0
Subarachnoid hemorrhage	0	0	0	0	0	0	0	0

^{^a}

Patients may have received more than one type/subtype of concomitant antithrombotic therapy.

^{^b}

Patients were taking salicylic acid and derivatives for indications besides platelet aggregation inhibition including pain management, fever, and other uses.

^{^c}

Among the five patients who received thrombolytics, three appeared to have been for prevention or treatment of central venous catheter occlusions, and two were for unknown reasons.

^{^d}

Bruising and hemorrhage/hematoma are subcategories of bleeding/bruising.